Brain Cancer

Tucatinib Combination Demonstrates Multiple Positive Responses in HER2-Positive Metastatic Breast Cancer

August 14, 2020

Multiple positive responses were observed in an exploratory efficacy analysis evaluating tucatinib in combination with trastuzumab and capecitabine in patients with previously treated HER2-positive metastatic breast cancer with brain metastases in the previously reported HER2CLIMB trial.

Omburtamab BLA Submitted for FDA Approval in CNS/Leptomeningeal Metastasis From Neuroblastoma

August 06, 2020

A completed Biologics License Application was submitted to the FDA for omburtamab, an investigation monoclonal antibody, which is intended for the treatment of pediatric patients with central nervous system/leptomeningeal metastasis from neuroblastoma.

Expert Says Olutasidenib Appears Safe as Monotherapy in Relapsed/Refractory IDH1-Mutant Gliomas

July 10, 2020

In an interview with Targeted Oncology, Macarena de la Fuente, MD, discussed the findings from a phase 1b/2 study of olutasidenib as treatment of patients with relapsed/refractory IDH1-mutated gliomas, either alone or in combination with azacitidine.

Investigators Employ a Range of Novel and Established Systemic Therapies for Advanced Glioblastoma

June 22, 2020

Treatment of glioblastoma has seen few advancements since the approval of temozolomide plus radiotherapy in 2005 for newly diagnosed disease. Recently, promising clinical data have reinvigorated hope for novel therapies in this tumor type.